Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
News about Chimerix, Inc. (NASDAQ: CMRX) centers on its work as a biopharmaceutical company developing medicines for patients facing deadly diseases, with a particular focus on rare and high-grade brain tumors. Recent press releases emphasize the company’s lead clinical program, dordaviprone (ONC201), in development for H3 K27M-mutant diffuse glioma.
Investors and followers of CMRX news will find updates on key regulatory milestones, including the U.S. Food and Drug Administration’s acceptance of Chimerix’s New Drug Application for dordaviprone in recurrent H3 K27M-mutant diffuse glioma, Priority Review status, and the assigned PDUFA target action date of August 18, 2025. Company news also highlights Rare Pediatric Disease Designation, Fast-Track Designation, and Orphan Drug Designation for dordaviprone in multiple regions.
Chimerix news releases describe ongoing clinical development activities, such as the Phase 3 ACTION trial in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation, and Phase 1 dose escalation studies of ONC206 to evaluate safety and pharmacokinetic data. Additional items include corporate events like participation in oncology and precision medicine forums and updates on equity inducement grants under Nasdaq Listing Rule 5635(c)(4).
Another major theme in recent CMRX coverage is the definitive agreement for Jazz Pharmaceuticals to acquire Chimerix for approximately $935 million in cash. News articles outline the transaction terms, expected closing timing subject to customary conditions, and how dordaviprone would fit within Jazz’s rare oncology portfolio. For readers tracking CMRX, this news stream provides a view into Chimerix’s clinical progress, regulatory interactions, and announced strategic transaction with Jazz.
Chimerix (CMRX) will host a live conference call on August 8, 2022, at 4:30 p.m. ET to discuss Q2 financial results and provide a business overview. This session will allow investors to gain insights into the company's performance for the quarter ending June 30, 2022. The call can be accessed via phone or live audio webcast. Chimerix focuses on developing medicines for patients with serious diseases, with its key program, ONC201, in clinical development for H3 K27M-mutant glioma.
Chimerix (NASDAQ:CMRX) announced a contract worth up to $25.3 million from the Public Health Agency of Canada for the procurement of TEMBEXA (brincidofovir). This agreement underscores the significance of TEMBEXA as a medical countermeasure. The delivery is expected to take place before Chimerix's pending transaction with Emergent BioSolutions. TEMBEXA is approved for smallpox and Chimerix will earn revenues before closing the Emergent deal and a 15%-20% royalty on future sales. The transaction's completion requires several conditions, including regulatory approvals.
Chimerix (NASDAQ:CMRX) announced a $9.3 million agreement to procure TEMBEXA® (brincidofovir) internationally, bolstering its role as a medical countermeasure. This contract aims to meet strategic stockpile needs and fulfill obligations linked to a potential BARDA contract. Chimerix's revenue from TEMBEXA before the pending transaction with Emergent BioSolutions will remain with the company, while post-transaction, it will earn royalties of 15% on international and 20% on U.S. sales exceeding 1.7 million treatment courses. Closing of the deal is contingent upon several conditions.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a corporate overview at the Jefferies Healthcare Conference on June 8, 2022, at 3:30 p.m. in New York City. The presentation will highlight Chimerix's mission to develop medicines to improve and extend the lives of patients with serious diseases. A live audio webcast of the presentation will be accessible on the Investor Relations section of Chimerix’s website and archived for 90 days.
Chimerix's leading clinical program, ONC201, targets H3 K27M-mutant glioma.
DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded corporate update at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET. An audio webcast of the presentation will be accessible on Chimerix's Investor Relations webpage and archived for approximately 90 days. Chimerix focuses on developing medicines to improve the lives of patients with serious diseases, with its leading program being ONC201 for H3 K27M-mutant glioma.
Chimerix (CMRX) has secured up to $337.5 million from Emergent BioSolutions through the sale of worldwide rights to TEMBEXA, with an upfront payment of $225 million. The company is shifting focus to the development of ONC201 for H3 K27M-mutant glioma, planning a Phase 3 study by year-end 2022. The DSTAT program has been terminated to streamline efforts. Financially, Chimerix reported a net loss of $24.8 million for Q1 2022, a decrease from a $97.4 million loss in Q1 2021, while revenues dropped to $15,000 from $1.4 million a year earlier.
Chimerix (NASDAQ:CMRX) announced a definitive agreement with Emergent BioSolutions to acquire exclusive rights to brincidofovir, including TEMBEXA, for $225 million plus potential milestone payments of up to $100 million. The deal enhances Chimerix's balance sheet, allowing focus on its development pipeline while maintaining participation in TEMBEXA's economics through royalties and milestone payments. Closing conditions include a procurement contract with BARDA. TEMBEXA, approved by the FDA for smallpox, represents a strategic asset in biodefense.
Chimerix (NASDAQ:CMRX) announced that Josh Allen, Ph.D., its Chief Technology Officer of Imipridones, will participate in a panel discussion titled “Exploring New Targets for Pediatric Brain Cancer.” This event is hosted by Maxim Group and is scheduled for May 19, 2022, at 9:00 a.m. ET. An audio webcast of the event will be accessible on Chimerix's Investor Relations website for approximately 90 days. Chimerix is dedicated to developing medicines that enhance and prolong patients' lives. Notably, the FDA approved its drug TEMBEXA for smallpox treatment in June 2021.
Chimerix (NASDAQ:CMRX) will host a live conference call on May 16, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and provide a business overview. The call can be accessed via phone or through a webcast on the company's website. Chimerix focuses on developing medicines for serious diseases and has received FDA approval for TEMBEXA for smallpox. Additionally, the company is advancing its clinical programs for ONC201 and dociparstat sodium (DSTAT) in oncology.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded talk at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. An audio webcast of the presentation will be accessible on Chimerix's Investor Relations website and archived for 90 days. Chimerix focuses on developing medicines for severe diseases, having received FDA approval for TEMBEXA to treat smallpox. The company's advanced clinical programs include ONC201 for glioma and dociparstat sodium (DSTAT) for acute myeloid leukemia.